← Leaderboards
Sarah Kathleen Tasian
Children'S Hosp Of Philadelphia
$5,299,505
Attributed
$10,910,817
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,910,817 · 4
By mechanism
U01$6,582,256 · 2
R01$3,480,276 · 1
K08$848,285 · 1
Top collaborators
- Kai Tan5 shared
- Terry J. Fry1 shared
- Mignon Lee-Cheun Loh1 shared
- Jun J. Yang1 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- David Brian Frank$1,696,348
- Ryan William Morgan$2,408,662
- Janis K. Burkhardt$26,445,256
- Rebecca Ganetzky$3,859,922
- Yang-Yang Ding$553,623
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildSignal TransductionHigh RiskOncogenicPhosphotransferasesPathway InteractionsCytokine ReceptorsMutationSamplingIn VivoSignal PathwayPhiladelphiaSmall MoleculeToxic EffectTranslational ResearchGenomicsBaseAcute Lymphocytic LeukemiaGeneticKinase InhibitorCell LineDrug TargetingPhiladelphia ChromosomeLeukemia
Grant awards (12)
Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia$3,480,276
R01 · FY2025 · CA
Towards rational design of combination therapeutic targets$446,027
U01 · FY2024 · CA
Towards rational design of combination therapeutic targets$509,159
U01 · FY2023 · CA
Towards rational design of combination therapeutic targets$524,014
U01 · FY2022 · CA
Towards rational design of combination therapeutic targets$640,892
U01 · FY2021 · CA
Towards rational design of combination therapeutic targets$511,423
U01 · FY2020 · CA
Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissions$3,950,741
U01 · FY2018 · CA
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia$169,657
K08 · FY2018 · CA · contact PI
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia$169,657
K08 · FY2017 · CA · contact PI
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia$169,657
K08 · FY2016 · CA · contact PI
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia$169,657
K08 · FY2015 · CA · contact PI
PI3K Pathway Inhibition for Philadelphia-Like Acute Lymphoblastic Leukemia$169,657
K08 · FY2014 · CA · contact PI